This project is to support the Case Comprehensive Cancer Center (Case CCC) of Case Western Reserve University (CWRU) as a Lead Academic Participating Site in the newly reorganized National Clinical Trials Network (NCTN). The NCTN is a national consortium of Cooperative Groups, Academic and Community institutions, and National Core Facilities working with the NCI to perform practice-changing clinical trials in oncology. This is primarily in the form of Phase 1 and III prospective multicenter trials, and the correlative scientific work associated with these trials. Our role is to promote and support the mission of the NCTN to improve outcomes for patients with cancer, through the following specific aims: 1. to accrue large numbers of patients to NCTN trials, regardless of which Cooperative Group is the coordinating center, with exemplary efficiency and data quality. This includes contributions of detailed biological specimens and cancer imaging/technical data. We have demonstrated a high level of success in this endeavor over several decades within the former cooperative group system, and will continue and further expand upon this productivity. 2. To provide leadership to the NCTN Cooperative Groups and their operations centers, as well as NCI oversight and advisory committees related to clinical trials research. Our faculty members have been and will continue to serve as study chairs, co-chairs, translational research collaborators, committee members and co-investigators for a broad range of clinical trials research within the NCTN system. 3. To collaborate with other members of the NCTN community on innovative, hypothesis-based research that will lead to practice-changing clinical trials. This includes working on bio specimens/translational analyses and clinical secondary analyses from NCTN clinical trials, as well as developing and performing pilot studies that may lead to future late-stage NCTN research (the latter is via collaboration with the Case CCC Developmental Therapeutics Program and the Phase I clinical trials effort (U01CA062502).

Public Health Relevance

Large, federally-funded multicenter national clinical trials are critical to developing practice-changing improvements in cancer care. This is particularly important for addressing questions that are understudied by the private sector, such as advances in surgery, radiation therapy and radiology, and research on rare types of cancer. The participation of major university-based medical centers such as ours will help the national clinical trials system to answer clinical research questions of great importance to improving the quantity and quality of survival of people with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180853-01
Application #
8605962
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-06-06
Project End
2019-02-28
Budget Start
2014-06-06
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$1,188,450
Indirect Cost
$438,639
Name
Case Western Reserve University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
Strickland, Stephen A; Sun, Zhuoxin; Ketterling, Rhett P et al. (2017) Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. Leuk Res 59:55-64
Goldstein, Lori J; Zhao, Fengmin; Wang, Molin et al. (2017) A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group ( Breast Cancer Res Treat 165:375-382
Kalinsky, Kevin; Lee, Sandra; Rubin, Krista M et al. (2017) A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 123:2688-2697

Showing the most recent 10 out of 18 publications